Skip to main content
NIH Record - National Institutes of Health

Large Trial Will Test Immune Modulators for Covid-19

Drs. Austin and Collins at telebriefing

NCATS director Dr. Christopher Austin (l) and NIH director Dr. Francis Collins at launch of an adaptive phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with Covid-19.

Photo: Chia-Chi Charlie Chang

Dr. Collins writes notes at meeting.

Collins takes notes during announcement of the ACTIV trial.

Photo: Chia-Chi Charlie Chang

On Oct. 15, NIH held a media telebriefing to announce the launch of an adaptive phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with Covid-19.

The trial, part of the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, aims to determine if modulating that immune response can reduce the need for ventilators and shorten hospital stays.

Speakers included NCATS director Dr. Christopher Austin and NIH director Dr. Francis Collins, as well as Operation Warp Speed therapeutics lead Dr. Janet Woodcock, Johnson & Johnson chief scientific officer Dr. Paul Stoffels and Bristol Myers Squibb chief medical officer Dr. Samit Hirawat.

The NIH Record

The NIH Record, founded in 1949, is the biweekly newsletter for employees of the National Institutes of Health.

Published 25 times each year, it comes out on payday Fridays.

Associate Editor: Carla Garnett
Carla.Garnett@nih.gov

Staff Writers:

Eric Bock
Eric.Bock@nih.gov

Dana Talesnik
Dana.Talesnik@nih.gov

Back to Top